Stephen P. Squinto, EVP, Research & Development at ALEXION PHARMACEUTICALS INC (ALXN), sold 101,683 shares at $105.86 ($10.9M) on 2012-07-27, disclosed to the SEC on 2012-07-31.
Scheduled sale ($10.9M) by EVP, Research & Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.86 | 25,680 | $2.7M | 24.9% |
| 2 | $106.14 | 668 | $71K | 0.7% |
| 3 | $106.93 | 19,069 | $2.0M | 18.7% |
| 4 | $107.75 | 38,951 | $4.2M | 38.5% |
| 5 | $108.88 | 16,300 | $1.8M | 16.3% |
| 6 | $105.01 | 1,015 |
| $107K |
| 1.0% |
| Total | $107.26 avg | 101,683 | $10.9M | 100% |
| Filing → |
| SWTX | BUY | 2019-09-19 | $5.0M | — | Filing → |
| ALXN | SELL | 2014-10-28 | $1.1M | — | Filing → |
| ALXN | SELL | 2014-10-07 | $1.7M | — | Filing → |